These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [The treatment of osteoporosis and bone resorption of alveoli with alendronate in rat model].
    Author: Wang X, Yang Z, Yu S.
    Journal: Zhonghua Kou Qiang Yi Xue Za Zhi; 2001 May; 36(3):193-6. PubMed ID: 11812340.
    Abstract:
    OBJECTIVE: To evaluate the anti-osteoporosis effect of alendronate on bone in rat model. METHODS: The osteoporosis and alveolar bone resorption animal model were established in rats. The experimental groups were given alendronate in 5 mg/kg BW by subcutaneous injection after first day of ovariectomy and dental ligature, three times a week for 6 weeks. All the animals were sacrifised 12 weeks after the operation. The blood samples were collected for determination of biochemical indices. The left femora and jaw bones were processed for histomorphometry. The right femora and mendibles were prepared for determination of bone density and bone biodynamics. RESULTS: As compared with the control groups(without alendronate), the values of experimental groups (with alendronate) were all significantly improved on bone density, bone anti-flexure ability and body weight. The alkaline phosphatase, calcium in serum of ovariectomy groups(without alendronate) were obviously increased. In the experimental group, however, these indices were close to normal levels. In histomorphometry, there were little inflammation in gingiva and no obvious bone resorption in the alveolar crests of the experimental groups; but there were obvious gingivitis and alveolar crests resorption of the control groups. CONCLUSIONS: Alendronate can effectively prevent bone loss to reduce osteoporosis in ovariectomized rats and prohibit pathological alveolar bone resorption.
    [Abstract] [Full Text] [Related] [New Search]